- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05673382
CrisisCope: ICBT for Psychological Symptoms Related to Life Crises.
CrisisCope: Internet-based CBT Intervention for Distress Related to Life Crises.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study is a randomized controlled trial about the effects of ICBT aiming to target psychological symptoms related to one or more life crises. Primary outcome measures are depressive symptoms (measured with Beck Depression inventory-II) and anxiety symptoms (measured with Generalized Anxiety Disorder-7). Other outcome measures used will for example be about adaptability, stress symptoms, sleep problems, post traumatic stress symptoms and quality of life.
Because the psychological impact of a life crisis can be diverse, between different people and between different kinds of crises, a transdiagnostic individually tailored treatment will be used that has been tested in several previous trials. This treatment has been adopted to target psychological symptoms related to life crises.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Östergötland
-
Linköping, Östergötland, Sweden, 58183
- Department of Behavioral Sciences and Learning, Linköping University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Experience psychological symptoms related to one or more life crises.
- 18 years or older
- Adequate ability to speak, read and write Swedish
- Having access to the internet and a smartphone, computer or other device
Exclusion Criteria:
- Severe psychiatric or somatic issues that makes participation harder or impossible
- Ongoing addiction
- Acute suicidality
- Other ongoing psychological treatment
- Recent (within the past three months) changes in dose of psychotropic medication or planned change during the treatment weeks
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Treatment group
Eight weeks of individually tailored ICBT, were participants receives in total 8 modules out of 20 possible depending on their current problems and described situation with weekly support by a therapist.
|
The intervention (the treatment) within this study is based on cognitive behavioral therapy principles and adapted to target psychological symptoms related to life crises.
The 20 modules that the intervention consists of include psycho-educational texts as well as examples and exercises.
|
|
No Intervention: Control group
The control group is a wait-list control condition.
Participants are instructed to wait.
After the treatment group has finished their treatment and post-treatment measures has been collected, the control group receive the same treatment as the treatment group got.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Beck Depression Inventory-II
Time Frame: Change between Baseline, end of treatment after eight weeks and follow-up at 12 months after treatment termination.
|
Measure of depressive symptoms.
Range for the total sum is between 0 and 63 with a higher score score indicating a higher level of depressive symptoms.
Clinical ranges for minimal, mild, moderate and severe major depressive disorder are considered to be 0-13, 14-19, 20-28, and 29-63 respectively.
|
Change between Baseline, end of treatment after eight weeks and follow-up at 12 months after treatment termination.
|
|
Generalized Anxiety Disorder-7
Time Frame: Change between baseline, end of treatment after eight weeks and follow-up at 12 months after treatment termination.
|
Measure of anxiety symptoms and worry.
When summing the points of the seven first questions, the scores are interpreted as mild, moderate and severe anxiety symptoms at 5-10, 11-15, and above 15 respectively
|
Change between baseline, end of treatment after eight weeks and follow-up at 12 months after treatment termination.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Brief Adjustment Scale-6
Time Frame: Change between baseline, end of treatment after eight weeks and follow-up at 12 months after treatment termination. Also, every week during the treatment weeks.
|
A measure of general psychological adjustment, consisting of six items.
The items are on a seven-point response scale with higher scores indicating lower general psychological adjustment.
|
Change between baseline, end of treatment after eight weeks and follow-up at 12 months after treatment termination. Also, every week during the treatment weeks.
|
|
Patient Health Questionnaire-9
Time Frame: Change between baseline, end of treatment after eight weeks and follow-up at 12 months after treatment termination.
|
Measure of depressive symptoms.
Possible range for the total sum is 0 to 27 (created by summing up the scores from each item) with a higher score indicating higher levels of depression.
Clinical cut-offs for mild, moderate, moderately severe and severe major depressive disorder are considered to be 5, 10, 15 and 20 respectively.
|
Change between baseline, end of treatment after eight weeks and follow-up at 12 months after treatment termination.
|
|
Perceived Stress Scale-14
Time Frame: Change between baseline, end of treatment after eight weeks and follow-up at 12 months after treatment termination.
|
A questionnaire that aims to measure symptoms of stress.
It contains of 14 items that are scored on a range between 0 (never) and 4 (very often).
The total score range is between 0-56 and a higher score reflects higher levels of perceived stress.
|
Change between baseline, end of treatment after eight weeks and follow-up at 12 months after treatment termination.
|
|
Insomnia Severity Index
Time Frame: Change between baseline, end of treatment after eight weeks and follow-up at 12 months after treatment termination.
|
Measure of insomnia severity and symptoms of disordered sleep.
Norm score ranges include low likelihood of sleep problems (0-7 points), some sleep problems (8-14 points), moderate sleep problems (15-21 points), severe sleep problems (22-28 points).
|
Change between baseline, end of treatment after eight weeks and follow-up at 12 months after treatment termination.
|
|
Alcohol Use Disorder Identification Test
Time Frame: Change between baseline, end of treatment after eight weeks and follow-up at 12 months after treatment termination.
|
A ten-item scoring tool to assess alcohol consumption, drinking behaviors, and alcohol-related problems.
Scores are ranging from 0-40 with higher scores indicating a higher level of alcohol use.
|
Change between baseline, end of treatment after eight weeks and follow-up at 12 months after treatment termination.
|
|
Impact of Events Scale-Revised
Time Frame: Change between baseline, end of treatment after eight weeks and follow-up at 12 months after treatment termination.
|
Assesses subjective distress caused by traumatic events.Items are rated on a five-point scale from 0 (not at all) to 4 (extremely).
Total score range between 0-88, with a higher score indicating more severe distress caused by the traumatic events.
|
Change between baseline, end of treatment after eight weeks and follow-up at 12 months after treatment termination.
|
|
Brunnsviken Brief Quality of Life Scale
Time Frame: Change between baseline, end of treatment after eight weeks and follow-up at 12 months after treatment termination.
|
Measure of quality of life with a total score ranging from 0 to 96 with a higher score indicating higher quality of life.
The scores of each of the six primary questions regarding perceived quality of life within an area of life are multiplied with the score of an item measuring the perceived importance of the area in question.
|
Change between baseline, end of treatment after eight weeks and follow-up at 12 months after treatment termination.
|
|
InCharge Financial Distress/Financial Well-Being Scale
Time Frame: Change between baseline, end of treatment after eight weeks and follow-up at 12 months after treatment termination.
|
A measure aiming to measure distress related to the individual's economic situation.
It consists of eight questions where the respondent gets to answer on a scale from 1 to 10.
|
Change between baseline, end of treatment after eight weeks and follow-up at 12 months after treatment termination.
|
|
Medical Outcome Study Social Support Survey
Time Frame: Change between baseline, end of treatment after eight weeks and follow-up at 12 months after treatment termination.
|
A 12-item questionnaire aiming to measure the individual's perceived social support that is answered on a five-point scale (1-5).
Besides the 12 items, the questionnaire also includes a question about how many family members and friends that the individual experience to have, who he/she can talk to.
Total score range between 12 to 60.
|
Change between baseline, end of treatment after eight weeks and follow-up at 12 months after treatment termination.
|
|
Posttraumatic Growths Inventory-Short form
Time Frame: Change between baseline, end of treatment after eight weeks and follow-up at 12 months after treatment termination.
|
A questionnaire consisting of 10 items, aiming to investigate the individual's experience of positive change in relation to challenging life events.
Each item are answered on a six-point scale ranging between 0 to 5, resulting in a total score range between 0-60.
|
Change between baseline, end of treatment after eight weeks and follow-up at 12 months after treatment termination.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Gerhard Andersson, PhD, University Hospital, Linkoeping
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CrisisCope
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depressive Symptoms
-
Aalborg University HospitalRecruitingDepressive Disorder | Depression | Depressive Episode | Depressive Disorders | Depressive Episodes | Depression - Major Depressive Disorder | Depressive Disorder, Major Depressive DisorderDenmark
-
University of California, San DiegoRecruitingDepressive Disorder | Depression | Depressive Symptoms | Major Depressive Disorder | Treatment Resistant DepressionUnited States
-
Finnish Institute for Health and WelfareUniversity of Helsinki; Tampere University; University of Eastern Finland; Strategic...RecruitingMajor Depressive Disorder | Depressive Symptoms Mild to Moderate in SeverityFinland
-
Julia EderNot yet recruitingDepressive Disorder | Depression | Depressive Symptoms | Major Depressive Disorder | Depressive EpisodeGermany
-
Mental Health Services in the Capital Region, DenmarkHospital del Mar Research Institute (IMIM); Research Centre of the German Foundation... and other collaboratorsEnrolling by invitationDepression - Major Depressive Disorder | Mental DistressSpain, Germany, Denmark
-
Medical Research CouncilKU LeuvenCompletedDepressive Symptoms | Major Depressive DisorderAustralia
-
Massachusetts General HospitalCompletedMajor Depressive DisorderUnited States, China
-
The Royal Ottawa Mental Health CentreNot yet recruitingDepression | Major Depressive Disorder (MDD) | Depressive Episode | Depression - Major Depressive DisorderCanada
-
Uppsala UniversityRecruitingPostpartum | Attachment | Depression - Major Depressive DisorderSweden
-
Dr. Nazanin AlaviCompletedDepression | Depressive Symptoms | Major Depressive DisorderCanada
Clinical Trials on Internet-based cognitive behavioral therapy
-
Karolinska InstitutetCompletedObsessive-compulsive DisorderSweden
-
University of TromsoUnknownComplicated Grief
-
Karolinska InstitutetUppsala UniversityRecruiting
-
Montefiore Medical CenterNational Center for Advancing Translational Sciences (NCATS)WithdrawnInflammatory Bowel Diseases | Psychological DistressUnited States
-
The Netherlands Cancer InstituteDutch Cancer Society; Pink Ribbon Inc.CompletedSexual Dysfunction | Breast Cancer Survivors | Intimacy ProblemsNetherlands
-
Linkoeping UniversityCompletedAnxiety Symptoms | Depression SymptomsSweden
-
Karolinska InstitutetCompleted
-
Université de SherbrookeCanadian Institutes of Health Research (CIHR)RecruitingSocial AnxietyCanada
-
Karolinska InstitutetDeakin UniversityRecruiting
-
University of Southern DenmarkNot yet recruitingAlcohol Use Disorder (AUD)